Moreover, CD147 depletion was demonstrated to substantially decrease MCT1 expression in those MM cells, suggesting that lenalidomide-mediated anti-myeloma activity detected from the in vitro model is not associated with disruption of CRBN-CD147-MCT1 axis. Here, CRBN is linked to Miyoshi myopathy.